Human Metabolome Technologies, Inc. (“HMT”)

Human Metabolome Technologies, Inc. (“HMT”), has signed a collaboration agreement with J-VPD, INC.

J-VPD, INC. provides clinical diagnostic testing services, as well as advanced medical devices and pharmaceuticals to more than 10 countries, with a primary focus on India through their subsidiary J-VPD Diagnostics India Private Limited.

The scope of this collaboration agreement is to offer laboratory testing services for research and clinical purposes, utilizing biomarkers ※ 1 for mental disorders and lifestyle-related diseases. At present, we will focus on the Indian market, which is sustaining a high economic growth, and striving for commercialization.

Mr. HASHIZUME Katsuhito, CEO of HMT stated, “We sincerely hope that our biomarker testing service will have an impact on maintaining health and preventing diseases of people all over the world. This partnership will become a major stepping stone for us to contribute to healthcare in India.”

HMT has commenced the above contract services and will further expand its business in the future.

About Human Metabolome Technologies, Inc. (“HMT”)

HMT is a biotech venture founded in 2003, based on the research achievements attained at the Institute for Advanced Biosciences (IAB), Keio University, Japan. HMT provides capillary electrophoresis mass spectrometry-based metabolomics services for researchers from companies and public research institutions. HMT is currently working on the development of clinical tests that utilize biomarkers for objective assessment of specific diseases. The company was listed on TSE Mothers in December 2013, on the 10th anniversary of its founding.